A5010627409- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Monoclonal and Polyclonal Antibodies Research
- Innovative Microfluidic and Catalytic Techniques Innovation
- Cellular Mechanics and Interactions
- T-cell and B-cell Immunology
- Microtubule and mitosis dynamics
- Fungal and yeast genetics research
Children's Hospital of Pittsburgh
2025
University of Pittsburgh
2025
University of Pittsburgh Medical Center
2024
Dana-Farber Cancer Institute
2018
Beth Israel Deaconess Medical Center
2015
The anti-tumor effects of chemotherapy and radiation are thought to be mediated by triggering G1/S or G2/M cell cycle checkpoints, while spindle poisons, such as paclitaxel, block metaphase exit initiating the assembly checkpoint. In contrast, we have found that 150 kilohertz (kHz) alternating electric fields, also known Tumor Treating Fields (TTFields), perturbed cells at transition from anaphase. Cells exposed TTFields during mitosis showed normal progression this point, but exhibited...
We developed a screening assay in which luciferized ID8 expressing OVA was cocultured with transgenic CD8+ T cells specifically recognizing the model antigen an H-2b-restricted manner. The screened small-molecule library to identify compounds that inhibit or enhance cell-mediated killing of tumor cells. Erlotinib, EGFR inhibitor, top compound enhanced T-cell Subsequent experiments erlotinib and additional inhibitors validated screen results. increased both basal IFNγ-induced MHC class-I...
Abstract As immune checkpoint blocking antibodies increasing become foundational therapies for the treatment of cancer, there is a pressing need to identify compounds that synergize with blockade as basis combinatorial regimens. We have developed screening assay in which luciferized tumor cell line expressing model antigen co-cultured transgenic CD8+ T specifically recognizing H-2b-restricted manner. The target cell/T was screened small molecule library inhibit or enhance cell-mediated...
Abstract T cell exhaustion remains a significant barrier to immunotherapeutic success for many patients with solid tumors. Growing evidence suggests that enhanced survival and self-renewal properties of stem-like precursor population (Tpex) is correlated advantage in immunotherapy. In recent study published Science, Kang colleagues find three epigenetic regulators commonly mutated clonal hematopoiesis also control Tpex progression exhaustion. By leveraging the finding myelodysplastic...
Abstract Immune Checkpoint Blockade (ICB) has revolutionized the treatment of patients with cancer but provides durable clinical benefit to only a minority patients. Neoantigens, antigens derived from tumor mutations, are emerging as key targets T cells in responses ICB whose tumors exhibit high mutational burden. specific some neoantigens appear be naturally generated these and can further expanded upon ICB. Accurate neoantigen identification may fuel therapeutic advances by driving potent...
Abstract A key goal in immuno-oncology is the identification of tumor antigens recognized by T cells. Significant progress has been made predicting MHC class I presentation tumor-specific (peptides) CD8 reactive However, CD4 cells that are presented II proven to be more challenging. Studies have shown binding affinity less predictive for than I. Class antigen-directed therapeutics require accurate antigen from patient samples, which remains elusive today. Methods: We focused initially on...